---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009326"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:09:57.734725+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Surrozen updates pipeline; cash $75.8M, net loss improves; SZN-043 and SZN-1326 timelines

## Summary
- Cash, equivalents and marketable securities $75.8M at Dec 31, 2022, down from $123.5M; runway into H2 2024.
- Collaboration revenue $12.5M from Boehringer Ingelheim deal; net loss improved to $36.0M from $54.6M in 2021.
- SZN-043: Phase 1a in chronic liver disease enrolled first patient, data expected end 2023; Phase 1b in severe alcoholic hepatitis in 2024.
- SZN-1326: expect to re-initiate Phase 1a in healthy volunteers mid-2023 with lower dose; Phase 1b UC data H2 2024.
- Boehringer partnership for SZN-413: potential $10M milestone upon lead candidate nomination by end 2023.

## SEC filing metadata
- accession: 0000950170-23-009326
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017023009326/0000950170-23-009326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017023009326/srzn-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009326
- JSON: https://secwatch.observer/filing/0000950170-23-009326.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.